BioSpace News Archive

Transparency Market Research has published a new report titled, “Coronary Artery Bypass Graft Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The global lipid disorders treatment market is estimated to grow at a significant rate, states Transparency Market Research, in its recent report.

Through an agreement with National Health Service and SobiTM, people living with haemophilia A in the United Kingdom will have increased access to Elocta following a successful bid in the United Kingdom’s haemophilia A tender.

Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing of the first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA®, MSD’s anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

Neuronetics, Inc., a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced the appointment of Bruce J. Shook to its Board of Directors and as a member of the Audit Committee effective immediately.

Applied DNA Sciences Inc. is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the U.S. market opens on June 29, according to a preliminary list of additions posted on June 19 to the Russell Reconstitution website.

Nemaura Medical, Inc. announced an interview with its CEO Dr. Faz Chowdhury will air on The RedChip Money Report television program.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that the Company has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes.

Helix BioPharma Corp. (TSX: HBP) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “ Divestment ”), Helix Immuno-Oncology S.A. (“ HIO ”), representing approximately

T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to four new employees.